Sanofi Pays Synthekine $40M to Join Preclinical Push against Vexing Inflammatory Target

Sanofi is paying $40 million to add another cytokine—IL-10—to its hit list. This has secured Sanofi the chance to work with Synthekine to overcome long-standing barriers to the use of the cytokine in the treatment of inflammatory diseases.